Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss

A longevity startup has dosed its archetypal diligent with a cause to reverse age-related show loss.

Life Biosciences is investigating its ER-100 drug, which has been shown to reconstruct imaginativeness successful monkeys, for information and broadside effects successful a survey of astir 18 adults implicit the adjacent year.

It volition beryllium targeting patients with glaucoma and NAION, 2 conditions causing harm to important cells successful the optic nerve, which transmits ocular accusation from the backmost of the oculus to the brain. ER-100 is designed to rejuvenate those cells truthful that they enactment again and reconstruct sight.

It is the archetypal ever cellular rejuvenation therapy utilizing this exertion to person FDA clearance to participate quality objective trials, and hence the archetypal accidental to trial whether the exertion tin “ameliorate quality disease,” according to Life Biosciences co-founder and prof of Genetics astatine Harvard Medical School, David Sinclair.

Aging biology – knowing however the body’s cells and functions deteriorate implicit clip – is astatine the basal of longevity science. ER-100 is the absorption of large involvement crossed biotech for its imaginable to reverse cellular aging. Life Biosciences, based successful Boston, says it is processing applications for its exertion to tackle a big of age-related diseases successful a assortment of organs, similar fatty liver disease.

“Our probe has suggested that aging is driven successful ample portion by the nonaccomplishment of epigenetic information, not irreversible damage. This objective survey represents the archetypal accidental to trial whether restoring that accusation tin ameliorate quality disease,” Sinclair said.